RSP systems
Non-invasive blood glucose monitoring.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €5.0m | Series C | |
| Total Funding | 000k | ||
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | 22 % | - | - | - | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | (630 %) | - | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (318 %) | (520 %) | - | - | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
RSP Systems is a pioneering startup focused on revolutionizing diabetes management through non-invasive glucose monitoring technology. The company, headquartered in Odense, Denmark, is dedicated to developing GlucoBeam, a device that allows individuals to monitor their blood glucose levels without the need for painful finger pricks or blood samples. This innovative approach aims to improve the quality of life for people with diabetes by providing a more convenient and less intrusive method of glucose monitoring.
RSP Systems primarily serves individuals with diabetes, a rapidly growing demographic. According to recent estimates, 415 million people worldwide suffer from diabetes, with projections indicating this number could rise to 642 million by 2040. In the United States alone, over 100 million people are affected by diabetes and pre-diabetes, leading to an annual healthcare cost exceeding $325 billion. The company's target market is vast and expanding, highlighting the significant demand for improved diabetes management solutions.
The business model of RSP Systems revolves around the development, validation, and commercialization of their GlucoBeam device. The company generates revenue through the sale of these devices, as well as potential partnerships and licensing agreements with healthcare providers and institutions. By offering a non-invasive alternative to traditional glucose monitoring methods, RSP Systems aims to capture a substantial share of the diabetes care market.
RSP Systems has made significant strides in the validation and development of their technology. The company's clinical trials, identified by ClinicalTrials.gov Identifier NCT03368209, have demonstrated the efficacy of their non-invasive glucose monitoring system. Additionally, RSP Systems has been recognized as a promising startup, joining the Soonicorn club of Denmark, which highlights its potential for rapid growth and success.
In summary, RSP Systems is setting a new standard in diabetes management with its non-invasive glucose monitoring technology. By addressing a critical need in the healthcare market, the company is well-positioned for future growth and success.
Keywords: Non-invasive, glucose monitoring, diabetes management, GlucoBeam, healthcare, innovation, startup, clinical trials, pain-free, technology.